middle.news

Independent review gives Paradigm’s iPPS program a possible second chance

8:40am on Thursday 19th of November, 2026 AEDT • Biotechnology
Read Story

Independent review gives Paradigm’s iPPS program a possible second chance

8:40am on Thursday 19th of November, 2026 AEDT
Key Points
  • Independent analysis confirms significant ROW benefits for pain, physical function and patient-reported improvement
  • Overall PARA_OA_012 futility result remains unchanged, with no clear advantage in the full population or US cohort
  • Paradigm plans to assess a new ROW trial as the near-term development priority
  • US development remains possible after further data review and FDA consultation
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE